Sign inJoin waitlistJoin the waitlist

Nitin Jain

Director, Cellular Therapy Program · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

Bone Marrow Aspiration Clinic · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Chicago Medical Center
2009–2012
University of Texas M D Anderson Cancer Center
2007–2008
Internal Medicine
Medical College of Wisconsin - Milwaukee
2004–2007
All India Institute of Medical Sciences
2002–2003
Doctor of Medicine
1999–2003

Research

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · 1,951 citations
Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · First of 32 authors · 426 citations
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
American Journal of Hematology · 2018 · 373 citations

Hagop Kantarjian
213 papers
Elias Jabbour
212 papers
Tapan Kadia
141 papers
Nicholas Short
137 papers · 16 as a fellow
William Wierda
125 papers · 8 as a fellow
Guillermo Garcia-Manero
124 papers
Marina Konopleva
117 papers
Naval Daver
106 papers
Naveen Pemmaraju
103 papers
Alessandra Ferrajoli
94 papers
Courtney DiNardo
92 papers
GB
Gautam Borthakur
86 papers

Grants

The Genetic Epidemiology of Rotator Cuff Tears: The cuffGEN Study
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
Contact PI · $3.6M · University of Michigan at Ann Arbor
2020–2027
Operative Versus Non-Operative Treatments for Atraumatic Rotator Cuff Tears: A Mutlicenter Randomized Controlled Trial
National Institute of Arthritis and Musculoskeletal and Skin Diseases · U34
Contact PI · $395K · Vanderbilt University Medical Center
2016–2019
Rotator Cuff Tears: Optimizing Diagnosis and Treatment Strategies
National Institute of Arthritis and Musculoskeletal and Skin Diseases · K23
Contact PI · $650K · Vanderbilt University
2010–2016

Clinical trials

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2029
Study Of KITE-753 in R/R B-Cell ALL
Principal investigator · Not yet recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2031
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2033
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2023